...
首页> 外文期刊>Breast cancer research and treatment. >Survival benefit of postoperative radiotherapy for ductal carcinoma in situ after breast-conserving surgery: a Korean population-based cohort study
【24h】

Survival benefit of postoperative radiotherapy for ductal carcinoma in situ after breast-conserving surgery: a Korean population-based cohort study

机译:术后放疗术后哺乳酸癌术后癌症外科术后的生存效益:韩国人口队列队列研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PurposeIt has been accepted that radiation therapy (RT) for ductal carcinoma in situ (DCIS) has no survival benefit despite increasing local control. However, a recent large database study reported a small but significant benefit. Using a Korean population-based large database, we examined the survival benefit of RT for DCIS after breast-conserving surgery (BCS) and analyzed which subgroup might derive benefit from it.MethodsData from 6038 female DCIS patients who underwent BCS with or without RT between 1993 and 2012 were included in this study. We used propensity score analysis to control for differences in baseline characteristics.ResultsBefore adjusting, patients who received RT were more likely to have a large-sized tumor, poor histologic grade, poor nuclear grade, and less hormone receptor positivity. Ten-year overall survival (OS) rates were 95.0% in the non-RT group and 97.1% in the RT group (p<0.001). After adjusting, previously noted differences of characteristics were substantially reduced, and then ten-year OS rates were 94.3% in the non-RT group and 97.6% in the RT group (p=0.001). When examining the benefit of RT according to proposed prognostic scores, patients with a score of 0 showed no difference in OS by adding RT after BCS, whereas those with high scores demonstrated a significant benefit.ConclusionsWe demonstrated the significant OS benefit of postoperative RT after BCS based on a large database, and for the first time beyond the western population. The omission of RT for selected patients to prevent overtreatment needs to be more elaborately studied.
机译:目的已经接受,尽管局部控制增加,但原位(DCIS)的导管癌的放射治疗(RT)没有生存效益。然而,最近的一个大型数据库研究报告了一个小而显着的益处。使用韩国人口的大型数据库,我们检查了哺乳手术(BCS)后进行DCIS的RT的存活效益,并分析了哪些亚组可能从中得到益处。来自6038名雌性DCIS患者的患者,他们在有或没有RT之间接受了BCS 1993年和2012年被纳入本研究。我们使用倾向评分分析来控制基线特征的差异。评论评估,接受RT的患者更可能具有大尺寸的肿瘤,组织学等学程度差,核级差和较少的激素受体阳性。在非RT组中为10年的总生存率(OS)率为95.0%,RT组中97.1%(P <0.001)。调整后,先前注意的特性差异显着降低,然后在非RT组中为10年的OS速率为94.3%,RT组中97.6%(P = 0.001)。当根据提出的预后评分检查RT的益处时,评分为0的患者通过BCS添加RT表明OS没有差异,而具有高分的人则表现出显着的益处.Conclusionswe在BCS之后证明了术后RT的显着os受益基于一个大型数据库,并在西方人群之外第一次。需要更精细地研究选择患者的RT遗漏,以防止过度处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号